Version 2.

Date of publication 24 December 2019

Date of implementation 19 March 2020

DS-G-031-V2.2/130416
 Data Requirements for Herbal &
Health Products Submission
Content of the Dossier

Version 2.2

Saudi Food & Drug Authority

Drug Sector

For Inquiries [email protected]

For Comments [email protected]

Please visit SFDA’s website at

https://www.sfda.gov.sa/en/regulations?tags=2

for the latest update

DS-G-031-V2.2/130416
 Saudi Food and Drug Authority

Vision and Mission

Vision

To be a leading international science-based regulator to protect and promote

public health

Mission

Protecting the community through regulations and effective controls to

ensure the safety of food, drugs, medical devices, cosmetics, pesticides and
feed

DS-G-031-V2.2/130416
 Document Control

Version Author Date Comments

Executive Directorate of
1.1 16 April 2013 Final
Products Evaluation

Executive Directorate of
1.2 12 February 2014 Update
Products Evaluation

Two drafts published for

public review:

Data Requirements For Health

Supplements Submission,
Executive Directorate of
Draft Date: 3 January 2019
-
Products Evaluation
Data Requirements For Herbal
& Health Products
Submission,

Date: 5 March 2019

Executive Directorate of Update based on companies

Draft 24 December 2019 comments and published for
Products Evaluation feedback purposes

Executive Directorate of Final version for

2.0 19 March 2020
Products Evaluation implementation

Executive Directorate of
2.1 10 August 2020 Update
Products Evaluation

Update
Executive Directorate of
2.2 06 June 2022
Products Evaluation (Next page shows the
updated details)

DS-G-031-V2.2/130416
 What is New in version no. 2.2?

The following table shows the update to the previous version:

Section Description of change

3.2.S.3.1 Elucidation of
Structure and Other Changed from "Required document" to "if applicable"
Characteristics

Add:
3.2.S.2.1
In the case of multiple sites, the role of each site should be
Manufacturer(s)
clarified.

3.2.S.2.2 Description of Add:

Manufacturing Process List of all residual solvents and their limits of control if any
and Process Controls were used during the manufacturing process.

Appendix 1 Update:
Isopropanol 70%.

DS-G-031-V2.2/130416
 Table of Contents
1. INTRODUCTION ....................................................................................................... 7

1.1. Objectives ............................................................................................................ 7

1.2. Background ......................................................................................................... 7

1.3. Scope .................................................................................................................... 7

1.4. Related guidelines............................................................................................... 7

2. DOCUMENTATION .................................................................................................. 8

Table 1: The CTD Structure for both health and herbal product submission ........ 8

2.1. Part 1 Administrative Information ................................................................. 11

2.2. Part 2 Technical Information .......................................................................... 13

The Recommended Types of Evidence to Support the safety and efficacy of a

Herbal and Health Product Submission (Module 5) ................................................ 34

3. APPENDIX ................................................................................................................... 37

Appendix 1 ................................................................................................................... 37

DS-G-031-V2.2/130416
 1. INTRODUCTION

1.1. Objectives

This guideline provides recommendations on the documentation requirements for

the registration of herbal & health products.

1.2. Background

The SFDA has classified products that fall under this guidance into two categories:
• Health Products.
• Herbal Products.
SFDA will employ a risk-based approach taking into consideration elements of the
product’s quality, safety and efficacy.

1.3. Scope

This guideline clarifies the requirements for registration of products that are
classified as herbal products or health products.
For more information, please refer to the SFDA’s Products Classification Guidance.

1.4. Related guidelines

• Guidance for Presenting PIL and Labeling Information of Herbal and Health Products

• General Rules for Products containing Vitamins and Minerals

• SFDA’s Products Classification Guidance

• Guidance for submission

DS-G-031-V2.2/130416
 2. DOCUMENTATION
Table 1: The CTD Structure for both health and herbal product
submission
Section Requirements
Module 1 Regional Administrative Information
1.0 Cover letter R1
1.1 Comprehensive table of content R
1.2 Application Form R
1.3 Product Information
1.3.1 Summary of Product Characteristics (SPC) O2
1.3.2 Labeling R
1.3.3 Patient information leaflet (PIL)
1.3.3.1 Arabic leaflet IA3
1.3.3.2 English leaflet IA
1.3.4 Artwork (Mock-ups) R
1.3.5 Samples R
1.7 Certificates and Documents
1.7.1 GMP Certificate R
1.7.2 CPP or Free-sales R
1.7.3 Certificate of analysis – Drug Substance / Finished Product R
1.7.4 Certificate of analysis – Excipients R
1.7.5 Alcohol-free declaration R
1.7.6 Pork- free declaration R
1.7.7 Certificate of suitability for TSE R
1.7.8 The diluents and coloring agents in the product formula IA
1.7.10 Letter of access or acknowledgment to DMF IA
1.7.11 Commercial Agency contract IA
1.8 Pricing
1.8.1 Price list IA
1.8.2 Other documents related IA
1.9 Responses to questions R

Module 3 Quality
3.1 Table of Contents of Module 3 R

1
R: Required
2
O: Optional (optional means that it might not be needed at this stage or not needed at all depending on
the product status and the course of the evaluation process)
3
IA: if applicable

DS-G-031-V2.2/130416
 3.2 Body of data
3.2.S Drug Substance
3.2.S.1 General Information
3.2.S.1.1 Nomenclature R
3.2.S.1.2 Structure R
3.2.S.1.3 General Properties R
3.2.S.2 Manufacture
3.2.S.2.1 Manufacturer(s) R
3.2.S.2.2 Description of Manufacturing Process and Process Controls R
3.2.S.2.3 Control of Materials O
3.2.S.2.4 Control of Critical Steps and Intermediates O
3.2.S.2.5 Process Validation and/or Evaluation O
3.2.S.2.6 Manufacturing Process Development O
3.2.S.3 Characterization
3.2.S.3.1 Elucidation of Structure and Other Characteristics IA
3.2.S.3.2 Impurities R
3.2.S.4 Control of Drug Substance
3.2.S.4.1 Specifications R
3.2.S.4.2 Analytical Procedures R
3.2.S.4.3 Validation of Analytical Procedures IA
3.2.S.4.4 Batch Analyses R
3.2.S.4.5 Justification of Specification R
3.2.S.5 Reference Standards or Materials IA
3.2.S.6 Container/Closure Systems O
3.2.S.7 Stability
3.2.S.7.1 Stability Summary and Conclusions O
3.2.S.7.2 Post-approval Stability Protocol and Commitment O
3.2.S.7.3 Stability Data O
3.2.P Drug Product
3.2.P.1 Description and Composition of the Drug Product R
3.2.P.2 Pharmaceutical Development
3.2.P.2.1 Components of the Drug Product
3.2.P.2.1.1 Drug substance(s) O
3.2.P.2.1.2 Excipients O
3.2.P.2.2 Drug Product
3.2.P.2.2.1 Formulation Development IA
3.2.P.2.2.2 Overages R
3.2.P.2.2.3 Physiochemical and Biological Properties IA
3.2.P.2.3 Manufacturing Process Development O
3.2.P.2.4 Container Closure System O
3.2.P.2.5 Microbiological Attributes O

DS-G-031-V2.2/130416
 3.2.P.2.6 Compatibility O
3.2.P.3 Manufacture
3.2.P.3.1 Manufacturer(s) R
3.2.P.3.2 Batch Formula R
3.2.P.3.3 Description of Manufacturing Process and Process Controls R
3.2.P.3.4 Controls of Critical Steps and Intermediates O
3.2.P.3.5 Process Validation and/or Evaluation O
3.2.P.4 Control of Excipients
3.2.P.4.1 Specifications R
3.2.P.4.2 Analytical Procedures O
3.2.P.4.3 Validation of Analytical Procedures O
3.2.P.4.4 Justification of Specifications IA
3.2.P.4.5 Excipients of Human or Animal Origin IA
3.2.P.4.6 Novel Excipients IA
3.2.P.5 Control of Drug Product
3.2.P.5.1 Specifications R
3.2.P.5.2 Analytical Procedures R
3.2.P.5.3 Validation of Analytical Procedures IA
3.2.P.5.4 Batch Analyses R
3.2.P.5.5 Characterization of Impurities IA
3.2.P.5.6 Justification of Specifications R
3.2.P.6 Reference Standards or Materials IA
3.2.P.7 Container/Closure System R
3.2.P.8 Stability
3.2.P.8.1 Stability Summary and Conclusions R
3.2.P.8.2 Post-Approval Stability Protocol and Stability Commitments R
3.2.P.8.3 Stability Data R
3.3 Literature References IA

Module 5 Clinical Study Reports

5.1 Table of Contents of Module 5 R
5.2 Tabular Listing of All Clinical Studies IA
5.3 Clinical Study Reports IA
5.4 Literature References IA

10

DS-G-031-V2.2/130416
 2.1. Part 1 Administrative Information

Module 1 Regional Administrative Information

1.0 Cover letter

The applicant shall include a cover letter for each submission.

1.1. Comprehensive table of content

The table of content for the entire submission should list all documents included in all
modules.

1.2. Application Form

The completed and signed application form printed out from the Saudi Drug Registration
(SDR) system should be presented in this section.

1.3. Product Information

This section contains the Labeling, Patient Information Leaflet (PIL) in Arabic and
English, Artwork and the Samples. (For more information, please refer to the Guidance for
Presenting PIL and Labeling Information of Herbal & Health Products). The leaflet in
Arabic and English should be provided if available.

1.7. Certificates and Documents

1.7.1. GMP Certificate
A valid GMP Certificate (or equivalent) should be submitted.

Note: the certificate must be issued from a regulatory agency and certified by the Saudi
embassy.

1.7.2. CPP or Free-sales

The CPP should be in accordance with WHO guidelines. However, if the CPP is not
available, a marketing authorization (or free sales certificate) from the country of origin
(COO) should be submitted.

1.7.3. Certificate of analysis – Drug Substance / Finished Product

- Certificates of analysis for at least one batch of the drug substance should be

11

DS-G-031-V2.2/130416
 submitted from the supplier (drug substance manufacturer).
- Certificates of analysis for at least one batch of the drug substance should be
submitted from the supplier finished product manufacturer.
- Certificates of analysis for more than one batch of the finished product should be
submitted.

1.7.4. Certificate of analysis – Certificate of analysis – Excipients

Specifications sheet from either supplier or finished product manufacturer should be
submitted.

In case of having a pharmacopeial excipient, the specifications sheet must cover all the
pharmacopeial parameters

1.7.5. Alcohol-free declaration

This section should contain a declaration letter in an official company letterhead stating
that the product is free from alcohol.

1.7.6. Pork- free declaration

This section should contain a declaration letter in an official company letterhead stating
that the product is free from any materials of pork/porcine source.

1.7.7. Certificate of suitability for TSE

This section should contain a declaration or valid TSE Certificate of Suitability issued by
the European Directorate for the Quality of Medicines (EDQM), which confirms the
compliance of a substance with the relevant monograph of the European Pharmacopoeia

1.7.8. The diluents and coloring agents in the product formula

This section should contain a declaration letter in an official company letterhead stating the
diluents and coloring agents used in the product formula, if any.

1.7.10. Letter of access or acknowledgment to DMF

If applicable, a letter written by the DMF Owner or authorized Agent permitting SFDA to
reference information in the DMF on behalf of the Applicant.

12

DS-G-031-V2.2/130416
 1.7.11. Commercial Agency contract
A valid commercial agency contract (or equivalent) should be submitted.

2.2. Part 2 Technical Information

Module 3 Quality

3.1 Table of Contents of Module 3

The table of content should list all documents included in Module 3.

3.2 Body of data

3.2.S Drug Substance (Active Ingredients)
A maximum of two active ingredient sources are acceptable at the initial submission. The
drug substance information can be submitted in one of the following options:

1. Certificate of suitability (CEP); or

2. Drug master file (DMF); or

3. Information on the “3.2.S drug substance” sections.

The drug substance information submitted should include the following for each of the
options used.

1. Certificate of Suitability (CEP)

A complete copy of the CEP (including any annexes) should be provided in Module 1.
Along with the CEP, the applicant should submit the following:

a) 3.2.S.1.3 General properties

Discussions on any additional applicable physicochemical and other relevant drug

substance properties that are not controlled by the CEP and Ph. Eur. monograph,
e.g. solubilities and polymorphs.

b) 3.2.S.3.1 Elucidation of structure and other characteristics

13

DS-G-031-V2.2/130416
 Studies to identify polymorphs (exception: where the CEP specifies a
polymorphic form) and particle size distribution, where applicable.

c) 3.2.S.4.1 Specifications

The specifications of the finished product manufacturer including all tests and
limits of the CEP and Ph. Eur. monograph and any additional tests and acceptance
criteria that are not controlled in the CEP and Ph. Eur. monograph, such as
polymorphs and/or particle size distribution.

d) 3.2.S.4.2 / 3.2.S.4.3 Analytical procedures and validation

For any tests in addition to those in the CEP and Ph. Eur. monograph.

e) 3.2.S.4.4 Batch analysis

Results from three batches of at least pilot scale, demonstrating compliance with
the finished product manufacturer’s API specifications.

f) 3.2.S.5 Reference standards or materials

Information on the finished product manufacturer’s reference standards.

g) 3.2.S.6 Container closure system

The specifications including descriptions and identification of primary packaging

components should be included in this section, except where the CEP specifies a
re-test period.

h) 3.2.S.7 Stability

The stability can be included in this section, except where the CEP specifies a re-
test period that is the same as or of longer duration than the re-test period proposed
by the applicant.

2. Drug Master File (DMF)

Full details of the chemistry, manufacturing process, quality controls during manufacturing
and process validation for the drug substance may be submitted as DMF. In such cases, the

14

DS-G-031-V2.2/130416
 Open part needs to be included in its entirety in the dossier as an annex to 3.2.S. In addition,
the applicant/finished product manufacturer can complete the following sections:

a) 3.2.S.1 General information 3.2.S.1.1 through 3.2.S.1.3.

b) 3.2.S.2 Manufacture

3.2.S.2.1 Manufacturer(s)

3.2.S.2.2 Description of manufacturing process and process controls

3.2.S.2.4 Controls of critical steps and intermediates

c) 3.2.S.3.1 Elucidation of structure and other characteristics

d) 3.2.S.3.2 Impurities

e) 3.2.S.4 Control of Drug Substance 3.2.S.4.1 through 3.2.S.4.5

f) 3.2.S.5 Reference standards or materials

g) 3.2.S.6 Container closure system

h) 3.2.S.7 Stability 3.2.S.7.1 through3 .2.S.7.1

3. Information on the “3.2.S Drug Substance” Sections.

Information on the 3.2.S Drug Substance sections, including relevant details of chemistry,
manufacturing process, quality controls during manufacturing for the drug substance,
should be submitted in the dossier as outlined in the subsequent sections of this guideline.

3.2.S.1 General Information

The qualitative and quantitative composition of all the constituents of the product should
be described as follows:

15

DS-G-031-V2.2/130416
 Active Substance(s):

Name(s) Quantity and/or percentage Reference

Excipient(s):

Name(s) Quantity and/or percentage Function Reference

3.2.S.1.1 Nomenclature
For herbal substance(s), the following information should be provided:

• Binomial scientific name of plant (genus, species, variety and author), and chemotype
(where applicable).

• Other names (synonyms mentioned in Pharmacopoeias).

• Parts of the plants.

• Laboratory code.

For the herbal preparation, the following information should be provided:

• Binomial scientific name of plant (genus, species, variety and author), and chemotype
(where applicable).

• Other names (synonyms mentioned in Pharmacopoeias).

• Parts of the plants.

• Laboratory code.

• Definition of the herbal preparation

• Ratio of the herbal substance to the herbal preparation.

16

DS-G-031-V2.2/130416
 • Extraction solvent(s).

• Possible addition of excipients (e.g. preservatives, carrier).

3.2.S.1.2 Structure
The following information, where applicable, should be provided:

• Physical form.

• Description of the constituents with known therapeutic activity or markers (molecular

formula, relative molecular mass, structural formula, including relative and absolute
stereochemistry, the molecular formula, and the relative molecular mass).

• Other constituent(s).

3.2.S.1.3 General Properties

A list should be provided of physicochemical and other relevant properties of the drug
substance. This includes the physical description, solubilities in common solvents,
polymorphism, pH and pKa values, UV absorption maxima and molar absorptivity,
melting point, refractive index (for liquids), hygroscopicity, partition coefficient, … etc.

3.2.S.2 Manufacture
3.2.S.2.1 Manufacturer(s)
The name(s) and complete postal address(es) of the manufacturing, packaging and testing
site(s) of the active ingredient(s) should be provided, In the case of multiple sites, the role
of each site should be clarified.

3.2.S.2.2 Description of Manufacturing Process and Process Controls

This applies to both health and herbal products. Additionally, for herbal substance(s),
information should be provided to adequately describe the plant production and plant
collection for herbal products, including:

• Geographical source of medicinal plant.

• Cultivation, time of harvesting, collection procedure (according to the Good
agricultural and collection practice for raw herbal materials) and storage conditions.

17

DS-G-031-V2.2/130416
 • Batch size.

For the herbal preparation, Information should be provided to adequately describe the
manufacturing process of the herbal preparation as follows, including data on the herbal
substance as described above.

• Description of processing (including flow diagram).

• Solvents, reagents.
• Purification stages.
• Standardisation.
• Batch size.
• A list of all residual solvents and their limits of control, if any, were used during
the manufacturing process.

3.2.S.2.3 Control of Materials

Materials used in the manufacture of the drug substance (e.g., raw materials, starting
materials, solvents, reagents, catalysts) can be listed identifying where each material is
used in the process. Information on the quality and control of these materials can be
provided in addition to information demonstrating that materials meet standards
appropriate for their intended use.

3.2.S.2.4 Control of Critical Steps and Intermediates

Critical Steps: Tests and acceptance criteria (with justification including experimental data)
performed at critical steps of the manufacturing process to ensure that the process is
controlled.

Intermediates: Information on the quality and control of intermediates isolated during the
process.

3.2.S.2.5 Process Validation and/or Evaluation

Process validation and/or evaluation studies for aseptic processing and sterilization.

3.2.S.2.6 Manufacturing Process Development

18

DS-G-031-V2.2/130416
 A brief summary describing the development of the herbal substance(s) and herbal
preparation(s) where applicable, taking into consideration the proposed route of
administration and usage. Results comparing the phytochemical composition of the herbal
substance(s) and herbal preparation(s) where applicable used in supporting bibliographic
data and the herbal substance(s) and herbal preparation(s) where applicable described in
S1 be discussed, where appropriate.

3.2.S.3 Characterization
3.2.S.3.1 Elucidation of Structure and Other Characteristics
For herbal substances

Information on the botanical, macroscopical, microscopical, phytochemical

characterization, and biological activity if necessary, should be provided.

For herbal preparations

Information on the phytochemical and physicochemical characterization, and biological

activity if necessary, should be provided.

3.2.S.3.2 Impurities
For herbal substances

As a general rule, herbal substances must be tested, unless otherwise justified, for
microbiological quality and for residues of pesticides and fumigation agents, toxic metals,
likely contaminants and adulterants, etc. The use of ethylene oxide is prohibited for the
decontamination of herbal substances.

For herbal preparations

In addition to the above, the concentration limits for process-related impurities (e.g.,
residual solvents) as per the applicable ICH guidance document should be discussed.

3.2.S.4 Control of Drug Substance

3.2.S.4.1 Specifications
A specification is a list of tests, references to analytical procedures, appropriate acceptance

19

DS-G-031-V2.2/130416
 criteria and reference of each tested parameter (e.g., USP, BP, in-house… etc). Copies of
the drug substance specifications, dated and signed by the concerned individual(s) should
be provided, including specifications for each drug substance manufacturer as well as those
of the finished product manufacturer.

In the case of herbal substance(s) described in a pharmacopoeia, applicant are expected to

follow pharmacopoeial specifications. Otherwise, the following specifications should be
submitted for non-pharmacopoeial herbal substance(s):

− Characteristics.

− Identification tests.

− Purity tests:

• Potential contamination by micro-organisms, products of micro-organisms,

pesticides, toxic metals, radioactivity, fumigants, …etc.
• Physical.
• Chemical.

− Assay(s) of constituents with known therapeutic activity or of markers, or other justified

determination.

For standardized herbal preparation, the content of constituents with known therapeutic
activity must be indicated with the lowest possible tolerance (with both upper and lower
limits). In the case of active markers used for quantified extracts the content of the markers
has to be given as a defined range. In the case of an analytical marker of an extract for
which neither constituents of known therapeutic activity, nor active markers are known,
the specified minimum and maximum content is related to the validated analytical range
as a base for analytical suitability within the frame of batch related control. The test
methods should be described in detail.

If preparations from herbal substances with constituents of known therapeutic activity are
standardized (i.e. adjusted to a defined content of constituents with known therapeutic
activity) it should be stated how such standardisation is achieved. If another substance is

20

DS-G-031-V2.2/130416
 used for these purposes, it is necessary to specify as a range the quantity that can be added.

3.2.S.4.2 Analytical Procedures

All analytical procedures used for testing of drug substance(s) should be provided.

Copies of the in-house analytical procedures used to generate testing results provided in
the dossier, as well as those proposed for routine testing of the drug substance by the
finished product manufacturer, should be provided. Unless modified, it is not necessary to
provide copies of the compendial analytical procedures.

3.2.S.4.3 Validation of Analytical Procedures (non-pharmacopeia)

Copies of the validation reports for the analytical procedures used to generate testing results
provided in the dossier, as well as those proposed for routine testing of the drug substance
by the finished product manufacturer, should be provided.

Validation data are not required for methods described in the Pharmacopeias.

3.2.S.4.4 Batch Analyses

Certificates of analyses should be submitted for at least two batches of each active
ingredient.

Description of batches and results of batch analyses should be provided. This would
include information such as batch number, batch size, date and site of production, …etc.

Certificates of analysis for at least two recent, commercial-scale production batches should
be provided. If data on commercial-scale batches are not available, certificates of analysis
should be provided for pilot-scale batches manufactured using the same process as intended
for commercial-scale batches.

The discussion of results should focus on observations noted for the various tests, rather
than reporting comments such as “all tests meet specifications”. For quantitative tests (e.g.
assay test, individual and total impurity tests), it should be ensured that actual numerical
results are provided rather than vague statements such as “within limits” or “conforms”.

21

DS-G-031-V2.2/130416
 3.2.S.4.5 Justification of Specification
Justification for the proposed specification(s) should be provided. This should include a
discussion on the inclusion of certain tests, analytical procedures and acceptance criteria.
If the compendial methods have been modified or replaced, a discussion should be
included. The justification for certain tests, analytical procedures and acceptance criteria
may have been discussed in other sections (e.g. impurities) and does not need to be repeated
here, although a cross-reference to their location should be provided.

3.2.S.5 Reference Standards or Materials

Information on the reference standards or reference materials used for testing of the drug
substance (including their source(s))should be provide

3.2.S.6 Container/Closure Systems

A description of the container closure system(s) can be provided, including the identity of
materials of construction of each primary packaging component, and their specifications.
The specifications include description, identification and critical dimensions with
drawings, where appropriate.

For non-functional secondary packaging components (e.g., those that do not provide
additional protection), only a brief description should be provided. For functional
secondary packaging components, additional information should be provided.

The suitability should be discussed with respect to, for example, choice of materials,
protection from moisture and light, compatibility of the materials of construction with drug
substance(s), including sorption to container and leaching, and/or safety of materials of
construction.

3.2.S.7 Stability

3.2.S.7.1 Stability Summary and Conclusions

The GCC guidelines for "Stability Testing of Active Pharmaceutical Ingredients and
Finished Pharmaceutical Products (FPPs)" should be consulted for recommendations on
the stability data required for the drug substance(s) and finished product(s).

22

DS-G-031-V2.2/130416
 The types of studies conducted, protocols used, and the results of the studies can be
summarized. The summary includes information on storage conditions, batch number,
batch size, container closure system and completed (and proposed) test intervals, results
and conclusions with respect to storage conditions and retest date or shelf-life, as
appropriate.

The discussion of results focuses on observations noted for the various tests, rather than
reporting comments such as “all tests meet specifications”. Where the methods used in the
stability studies are different from those described in S.4.2, descriptions and validation of
the methodology used in stability studies can be provided.

3.2.S.7.2 Post-approval Stability Protocol and Commitment

The post-approval stability protocol and stability commitment can be provided. In case
long-term stability data do not cover the proposed re-test period granted at the time of
assessment of the dossier, a commitment should be made to continue the stability studies
in order to firmly establish the re-test period. A written commitment (signed and dated) to
continue long- term testing over the re-test period should be included in the dossier when
relevant.

3.2.S.7.3 Stability Data

Results of the stability studies can be presented in a tabular format and data for all testing
parameters per each batch should be presented in one summary table. For quantitative tests
(e.g. individual and total degradation product tests and assay tests), it should be ensured
that actual numerical results are provided rather than vague statements such as “within
limits” or “conforms”. Information on the analytical procedures used to generate the data
and validation of these procedures can be included.

3.2.P Drug Product

3.2.P.1 Description and Composition of the Drug Product
A description of the product and its composition should be provided. The information
provided should include, for example:

23

DS-G-031-V2.2/130416
 • Description of the dosage form;

• Composition, i.e.:

− list of all components of the dosage form,

− their amount on a per-unit basis (including overages, if any),

− the function of the components, and

− a reference to their quality standards (e.g., compendial monographs or

manufacturer’s specifications);

• Description of accompanying reconstitution diluent(s); and

• Type of container and closure used for the dosage form and accompanying reconstitution
diluent, if applicable.

3.2.P.2 Pharmaceutical Development

3.2.P.2.1 Components of the Drug Product
3.2.P.2.1.1 Drug substance(s)
The compatibility of the drug substance(s) with excipients listed in 3.2.P.2.1.2 can be
discussed. Additionally, key physicochemical characteristics (e.g., water content,
solubility, particle size distribution) of the drug substance(s) that can influence the
performance of the product are to be discussed. For combination products, the
compatibility of drug substances with each other are to be discussed.

3.2.P.2.1.2 Excipients
The choice of excipients, their concentration, their characteristics that can influence the
performance of the product is expected be discussed relative to their respective functions.

3.2.P.2.2 Drug Product

3.2.P.2.2.1 Formulation Development

A brief summary describing the development of the product, taking into consideration the
proposed route of administration and usage. Results comparing the phytochemical

24

DS-G-031-V2.2/130416
 composition of the products used in supporting bibliographic data and the product
described in 3.2.P.1 can be discussed, where appropriate.

3.2.P.2.2.2 Overages
Any overages added to the formulation should be justified. If overages are added to
compensate for losses of the active ingredient(s) during the manufacturing process, the
stage(s) of manufacture where the loss of active ingredient(s) occurs should be identified.
Overages for the sole purpose of extending the shelf-life of the finished product are
generally not acceptable.

3.2.P.2.2.3 Physiochemical and Biological Properties

Parameters relevant to the performance of the product, such as pH, ionic strength,
dissolution, redispersion, reconstitution, particle size distribution, aggregation,
polymorphism, rheological properties, biological activity or potency, and/or
immunological activity.

3.2.P.2.3 Manufacturing Process Development

The selection and optimization of the manufacturing process and, in particular its critical
aspects, should be explained. The scientific rationale for the choice of the manufacturing,
filling, and packaging processes that can influence drug product quality and performance
can be discussed. The equipment can be identified by type and working capacity.

3.2.P.2.4 Container Closure System

The suitability of the container closure system (described in 3.2.P.7) used for the storage,
transportation (shipping) and use of the product is to be discussed. This discussion should
consider, e.g., choice of materials, protection from moisture and light, compatibility of the
materials of construction with the dosage form (including sorption to container and
leaching), and performance (such as reproducibility of the dose delivery from the device
when presented as part of the product). In case of using new packaging materials, the
discussion should include the safety of those materials, in addition to the above mentioned

25

DS-G-031-V2.2/130416
 requirements.

For a device accompanying a multidose container, the discussion should provide the results
that demonstrate the reproducibility of the device (e.g. consistent delivery of the intended
volume), generally at the lowest intended dose.

3.2.P.2.5 Microbiological Attributes

Where appropriate, the microbiological attributes of the dosage form should be discussed,
including, for example, the rationale for not performing microbial limits testing for non-
sterile products and the selection and effectiveness of preservative systems in products
containing antimicrobial preservatives. A single primary stability batch of the finished
product should be tested for effectiveness of the antimicrobial preservative (in addition to
preservative content) at the proposed shelf-life for verification purposes, regardless of
whether there is a difference between the release and shelf-life acceptance criteria for
preservative content.

3.2.P.2.6 Compatibility

The compatibility of the product with reconstitution diluent(s) or dosage devices (e.g.,
precipitation of substance(s) in solution, stability) can be addressed to provide appropriate
and supportive information for the labeling.

3.2.P.3 Manufacture
3.2.P.3.1 Manufacturer(s)
The Name (s) and complete postal address (es) of the manufacturing, packaging and testing
site (s) of the finished product should be provided.

3.2.P.3.2 Batch Formula

A batch formula should be provided that includes a list of all components of the dosage
form to be used in the manufacturing process, their amounts on a per batch basis, including
overages for each proposed commercial batch size and the total weight or measure of the
batch. All components used in the manufacturing process should be declared, including
those that may be removed during processing (e.g. solvents). The source material of each

26

DS-G-031-V2.2/130416
 medicinal ingredient should also be described.

3.2.P.3.3 Description of Manufacturing Process and Process Controls

A flow diagram and a narrative description of the process should be presented and should
include steps at which process controls are conducted.

3.2.P.3.4 Controls of Critical Steps and Intermediates

Appropriate tests and acceptance criteria (with justification, including experimental data)
for critical steps identified in 3.2.P.3.3 of the manufacturing process to ensure that the
process is controlled. Information on the quality and control of intermediates isolated
during the process can be provided.

3.2.P.3.5 Process Validation and/or Evaluation

Description, documentation, and results of the validation and/or evaluation studies can be
provided for critical steps or critical assays used in the manufacturing process (e.g.,
validation of the sterilization process or aseptic processing or filling).

3.2.P.4 Control of Excipients

3.2.P.4.1 Specifications
The specifications should be provided for all excipients, including non-medicinal
ingredient: standard or grade, approved name, common name, purpose, quantity, unit, and
source information.

3.2.P.4.2 Analytical Procedures

The analytical procedures used for testing the excipients can be provided, where
appropriate. Copies of the in-house analytical procedures used to generate testing results
should be provided. Unless modified, it is not necessary to provide copies of the
compendial analytical procedures.

3.2.P.4.3 Validation of Analytical Procedures

Analytical validation information, including experimental data, for the non-compendial

analytical procedures used for testing the excipients can be provided.

27

DS-G-031-V2.2/130416
 3.2.P.4.4 Justification of Specifications

Justification for the proposed excipient specifications should be provided in case of in-
house specifications.

3.2.P.4.5 Excipients of Human or Animal Origin

Excipients that are of human or animal origin (including country of origin) are to be listed.
Summary of the information (e.g., sources, specifications, description of the testing
performed, viral safety data) regarding adventitious agents for excipients of human or
animal origin should be provided.

For excipients obtained from sources that are at risk of transmitting Bovine Spongiform

Encephalopathy (BSE)/Transmissible Spongiform Encephalopathy (TSE) agents (e.g.,

ruminant origin), a letter of attestation (with supporting documentation) should be provided
confirming that the material is not from a BSE/TSE affected country/area. When available,
a CEP demonstrating TSE-compliance should be submitted. A complete copy of the CEP
(including any annexes) should be provided in Module 1.

3.2.P.4.6 Novel Excipients

For excipient(s) used for the first time in a product or by a new route of administration, full
details of manufacture, characterization, and controls, with cross references to supporting
safety data (non-clinical and/or clinical) should be provided

3.2.P.5 Control of Drug Product

3.2.P.5.1 Specifications

A copy of the specifications for the finished product signed and dated by authorized
personnel (person in charge of quality control or quality assurance department) should be
submitted.

3.2.P.5.2 Analytical Procedures

The analytical procedures used for testing the product should be provided. Copies of non-

28

DS-G-031-V2.2/130416
 compendial analytical procedures used during pharmaceutical development (if used to
generate testing results provided in the dossier) as well as those proposed for routine testing
should be provided. Unless modified, it is not necessary to provide copies of the
compendial analytical procedures.

3.2.P.5.3 Validation of Analytical Procedures

Analytical validation information, including experimental data, for the analytical

procedures used for testing the drug product, should be provided (in accordance with
ICH Q2(R1) and Q6B). Copies of the validation reports for the in-house analytical
procedures used during pharmaceutical development (if used to support testing results
provided in the dossier) as well as those proposed for routine testing should be provided.

Verification of compendial methods can be necessary. The compendial methods, as

published, are typically validated based on drug substance or a finished product originating
from a specific manufacturer. Different sources of the same drug substance or finished
product can contain impurities and/or degradation products or excipients that were not
considered during the development of the monograph. Therefore, the monograph and
compendial method(s) should be demonstrated suitable for the control of the proposed
finished product.

For compendial assay methods, verification should include a demonstration of specificity,

accuracy and repeatability (method precision). If a compendial method is used to control
related substances that are not specified in the monograph, full validation of the method is
expected with respect to those related substances.

If a compendial standard is claimed and an in-house method is used in lieu of the

compendial method (e.g. for assay or related substance), equivalency of the in-house and
compendial methods should be demonstrated. This could be accomplished by performing
duplicate analyses of one sample by both methods and providing the results from the study.
For related substance methods, the sample analyzed should be the placebo spiked with
related substances at concentrations equivalent to their specification limits.

3.2.P.5.4 Batch Analyses

29

DS-G-031-V2.2/130416
 Certificates of analyses should be submitted for at least two batches of the finished product.

3.2.P.5.5 Characterization of Impurities

Information on the characterization of impurities should be provided, if not previously

provided in "3.2.S.3.2 Impurities". The discussion should be provided for all impurities
that are potential degradation products and finished product process-related impurities.

3.2.P.5.6 Justification of Specifications

Justification for the proposed drug product specification(s) should be provided. The
discussion should be provided on the omission or inclusion of certain tests, evolution of
tests, analytical procedures, and acceptance criteria, differences from compendial
standard(s), etc. If the compendial methods have been modified or replaced, a discussion
should be included.

The justification for certain tests, analytical procedures and acceptance criteria (e.g.
degradation products) may have been discussed in other sections of the dossier and does
not need to be repeated here, although a cross-reference to their location should be
provided.

3.2.P.6 Reference Standards or Materials

Information on the reference standards or reference materials used for testing of the product
should include the following, if not previously provided in "3.2.S.5 Reference Standards
or Materials":

1. The source of reference standards or reference materials (e.g., House, USP, BP, Ph.
Eur.).

2. Certificate of analysis for reference standards or reference materials.

3. Characterization and evaluation of non-official (e.g., non-compendial) reference

standards or reference materials (e.g., method of manufacture, elucidation of structure,
certificate of analysis, calibration against an official standard).

3.2.P.7 Container/Closure System

30

DS-G-031-V2.2/130416
 A description of the container-closure system should be provided, including the identity of
materials of construction of each primary and secondary packaging component.

3.2.P.8 Stability

3.2.P.8.1 Stability Summary and Conclusions

Every manufacturer should define the period of time during which, after being packaged
for sale, the product will maintain its purity and physical characteristics and its medicinal
ingredients will maintain their quantity per dosage unit and their potency. Therefore, the
sponsor of the products is responsible for the shelf life. The sponsor must ensure that
stability data exists to support the shelf life. The shelf life must be based on scientific data.
SFDA may check the data through the internal regulatory mechanisms. The maximum shelf
life permitted is five years and applies to the product in its final container. The maximum
shelf life permitted is five years and applies to the product in its final container. Long-term
stability study performed at storage condition (25 oC ± 2 oC / 60% RH ± 5% RH) can be
accepted, however for products containing chemically synthesized material(s) (e.g.:
antiseptic or antilice..etc), the study should be conducted at (30 oC ± 2 oC / 65% RH ± 5%
RH).

3.2.P.8.2 Post-approval Stability Protocol and Stability Commitments

The post-approval stability protocol and, if applicable, stability commitment should be

provided. When the available long-term stability data on primary batches do not cover the
proposed shelf- life period granted at the time of assessment of the dossier, a commitment
should be made to continue the stability studies in order to firmly establish the shelf-life
period. A written commitment (signed and dated) to continue long-term testing over the
shelf-life period should be included in the dossier.

Where the submission includes long-term stability data on three production batches
covering the proposed shelf-life period, a post-approval commitment is considered

31

DS-G-031-V2.2/130416
 unnecessary. Otherwise one of the following commitments should be made:

− If the submission includes data from stability studies on three production batches, a
written commitment (signed and dated) should be made to continue these studies through
the proposed shelf-life period.

− If the submission includes data from stability studies on less than three production
batches, a written commitment (signed and dated) should be made to continue these studies
through the proposed shelf-life period and to place additional production batches, to a total
of at least three, in long-term stability studies through the proposed shelf-life period.

− If the submission does not include stability data on production batches, a written
commitment (signed and dated) should be made to place the first three production batches
on long term stability studies through the proposed shelf-life period.

The stability protocol for the commitment batches should be provided and should include,
but not be limited to, the following parameters:

• Number of batch(es) and different batch sizes, if applicable;

• Relevant physical, chemical, microbiological and biological test methods;

• Acceptance criteria;

• Reference to test methods;

• Description of the container closure system(s);

• Testing frequency; and

• Description of the conditions of storage.

The stability of the drug product should be monitored over its shelf-life to determine that
the product remains within its specifications and to detect any stability issue (e.g. changes
in levels of degradation products). For this purpose, the ongoing stability programme
should include at least one production batch per year of product manufactured in every
strength and every container closure system (unless none is produced during that year).

32

DS-G-031-V2.2/130416
 Therefore, a written commitment (signed and dated) for ongoing stability studies should
be included in the dossier.

Any differences in the stability protocols used for the primary batches and those proposed
for the commitment batches or ongoing batches should be scientifically justified.

3.2.P.8.3 Stability Data

Results of the stability studies for at least 12 months should be available at submission and
presented in a tabular format. The results of all testing parameters related to each batch for
the entire testing period should be presented in one table (i.e. presenting the results of one
parameter of all batches in one table is not acceptable).

The actual stability results/reports used to support the proposed shelf-life should be
provided in the dossier. For quantitative tests (e.g. individual and total degradation product
tests and assay tests), it should be ensured that actual numerical results are provided rather
than vague statements such as “within limits” or “conforms”. Dissolution results should be
expressed at minimum as both the average and range of individual results. Information on
the analytical procedures used to generate the data and validation of these procedures
should be included. Information on characterization of impurities is located in 3.2.P.5.5.

3.3 Literature References

A list and copies of all bibliographical references cited in support of this application should
be provided. References that have not been provided should be available upon request.

Module 5 Clinical Study Reports

5.1 Table of Contents of Module 5

The table of content should list all documents included in Module 5.

5.2 Tabular Listing of All Clinical Studies

If data is available or have been requested it should be presented in a tabular format to

33

DS-G-031-V2.2/130416
 facilitate the understanding and evaluation of the results.

5.3 Clinical Study Reports

Efficacy of the product as well as information on the safety of use should be addressed in
this section. For more information regarding evidence to support herbal and health product
applications.

5.4 Literature References

A list of cited references should be provided. References that have not been provided
should be available upon request.

The Recommended Types of Evidence to Support the safety and efficacy of

a Herbal and Health Product Submission (Module 5)

Introduction

Applicants must submit evidence from all relevant sources to support the safety and
efficacy of the product. The required evidence will vary depending on the type of claim
as well as the type of the product.

1. Herbal Product:

Products containing herbs are divided into two categories depending on the nature and
the intended usage of the herbal product:

1.1. Traditional herbal products

Traditional medicine (TM) refers to the knowledge, skills and practices based on the
theories, beliefs and experiences indigenous to different cultures. For products to be
considered ‘Traditional’, they should meet at least one or more of the following criteria:

• A period of at least 30 years of traditional use. The dose and the method of
preparation must be the same as those traditionally used.

• A corresponding product registered in any of the Stringent Regulatory Authorities

(US FDA, EMA, MHRA, SwissMedic, Health Canada and TGA). The corresponding

34

DS-G-031-V2.2/130416
 product should have the same active ingredients, indication, strength, pharmaceutical
dosage form, dosing frequency and the same route of administration.

• A corresponding product registered by the SFDA. The corresponding product should

have the same active ingredients, indication, strength, pharmaceutical dosage form,
dosing frequency and the same route of administration.

Sources of evidence of traditional usage include:

• Regulatory documents related to traditional use, e.g. assessment report, community

herbal monograph etc.

• Official expert committee reports or monographs from learned societies, e.g. WHO,
Commission E, ESCOP etc

• Bibliographic evidence, e.g. pharmacopoeia

• Published information referring to specific product formulations, e.g. Old editions:

Martindale: List of Preparations; Potter’s New Cyclopaedia etc.

• List of traditionally used herbs currently in use in Stringent Regulatory Authorities.

Note: The supporting evidence must show that product has been used in practice for at
least 30 years. Reference to a source published 30 years ago is not sufficient, as this
simply demonstrates that the product was in use 30 years ago. There must also be a
connection between the duration of use and the claimed use.

1.2. Non-Traditional herbal products (Stand-alone application):

Non-traditional herbal products must be supported by scientific evidence. Sources of
acceptable evidence include:

• Clinical Studies: Evidence from clinical studies can provide valuable information
about the efficacy and safety of the herbal product. There are several types of clinical
studies, including; systematic reviews, such as meta-analyses of randomized
controlled trial, randomized controlled trials and non-experimental observational
studies, such as epidemiological, cohort studies.

35

DS-G-031-V2.2/130416
 • Regulatory documents e.g. assessment report, community herbal monograph etc.

2. Health Product:

Depending on the nature and status of the health product, sources of acceptable evidence
include:

• Clinical Studies: Evidence from clinical studies can provide valuable information
about the efficacy and safety of the herbal product. There are several types of clinical
studies, including; systematic reviews, such as meta-analyses of randomized
controlled trial, randomized controlled trials and non-experimental observational
studies, such as epidemiological, cohort studies.

• Regulatory documents e.g. assessment report, community herbal monograph etc.

36

DS-G-031-V2.2/130416
 3. APPENDIX

Appendix 1
This appendix is a part of the “Data Requirement for Herbal and Health Products
Submission” and addresses health products that have previously been required to be listed
at the Saudi Food and Drug Authority and are now required to be registered as Health
product in order to be marketed in Saudi Arabia.

This group of products includes the following:

1. Alcohol hand sanitizers composed of these ingredients:

- Ethanol 60-80%.
- Isopropanol 70 %.
2. Throat lozenges which consist only of volatile oils, ascorbic acid (or its salts) and
at least menthol with no unacceptable claim and at a concentration of 5 mg or
higher. The concentration of the individual ingredients (menthol, eucalyptus oil and
Ascorbic acid) must not exceed the maximum value as follows:
- Menthol 5-20 mg
- Eucalyptus oil 0.5-15 mg
- Ascorbic acid 100 mg
3. Topical products containing organic acids (Alpha-hydroxy acids (AHAs)) where
the total concentration of organic acids is higher than 10%.
4. Skin Care Products containing urea in a concentration greater than the
recommended by the GSO standards for cosmetic products.
5. Aromatic and medicinal herbal oils that contain one or more of the oils that are
extracted from medicinal plants, that have non nutritional claims and are used
internally.
6. Products containing medicinal herbs that are not in their natural form and have gone
through any manufacturing processes such as grinding, extraction, packaging or
any other manufacturing process.
7. Insect repellents in direct contact with human skin.

37

DS-G-031-V2.2/130416
 8. Topical patches, creams, ointments and gels containing counter irritant ingredient
as an externally applied substance that causes irritation or mild inflammation of the
skin for the temporary relieve of pain in muscles or joints by reducing inflammation
in deeper adjacent structures (these products should comply with the Canadian
Counterirritant monograph).

The following requirements are considered minimum at the time of submission and are
subject to change. The Saudi Food and Drug Authority reserves the right to request
additional documents on a case-by-case basis:

Section Requirements
Module 1 Regional Administrative Information
1.0 Cover letter R
1.1 Comprehensive table of content R
1.2 Application Form R
1.3 Product Information
1.3.1 Summary of Product Characteristics (SPC) O
1.3.2 Labeling R
1.3.3 Patient information leaflet (PIL)
1.3.3.1 Arabic leaflet IA
1.3.3.2 English leaflet IA
1.3.4 Artwork (Mock-ups) R
1.3.5 Samples R
1.7 Certificates and Documents
1.7.1 GMP Certificate O
1.7.2 CPP or Free-sales R
1.7.3 Certificate of analysis – Drug Substance / Finished Product IA
1.7.4 Certificate of analysis – Excipients O
1.7.5 Alcohol-free declaration IA
1.7.6 Pork- free declaration R
1.7.7 Certificate of suitability for TSE IA
1.7.8 The diluents and coloring agents in the product formula IA
1.7.10 Letter of access or acknowledgment to DMF IA
1.7.11 Commercial Agency contract IA

38

DS-G-031-V2.2/130416
 1.8 Pricing
1.8.1 Price list IA
1.8.2 Other documents related IA
1.9 Responses to questions R

Module 3 Quality
3.1 Table of Contents of Module 3 R
3.2 Body of data
3.2.S Drug Substance
3.2.S.1 General Information
3.2.S.1.1 Nomenclature O
3.2.S.1.2 Structure O
3.2.S.1.3 General Properties O
3.2.S.2 Manufacture
3.2.S.2.1 Manufacturer(s) R
3.2.S.2.2 Description of Manufacturing Process and Process Controls O
3.2.S.2.3 Control of Materials O
3.2.S.2.4 Control of Critical Steps and Intermediates O
3.2.S.2.5 Process Validation and/or Evaluation O
3.2.S.2.6 Manufacturing Process Development O
3.2.S.3 Characterization
3.2.S.3.1 Elucidation of Structure and Other Characteristics O
3.2.S.3.2 Impurities O
3.2.S.4 Control of Drug Substance
3.2.S.4.1 Specifications O
3.2.S.4.2 Analytical Procedures O
3.2.S.4.3 Validation of Analytical Procedures O
3.2.S.4.4 Batch Analyses O
3.2.S.4.5 Justification of Specification O
3.2.S.5 Reference Standards or Materials O
3.2.S.6 Container/Closure Systems O
3.2.S.7 Stability
3.2.S.7.1 Stability Summary and Conclusions O
3.2.S.7.2 Post-approval Stability Protocol and Commitment O
3.2.S.7.3 Stability Data O
3.2.P Drug Product
3.2.P.1 Description and Composition of the Drug Product R
3.2.P.2 Pharmaceutical Development
3.2.P.2.1 Components of the Drug Product
3.2.P.2.1.1 Drug substance(s) O

39

DS-G-031-V2.2/130416
 3.2.P.2.1.2 Excipients O
3.2.P.2.2 Drug Product
3.2.P.2.2.1 Formulation Development O
3.2.P.2.2.2 Overages O
3.2.P.2.2.3 Physiochemical and Biological Properties O
3.2.P.2.3 Manufacturing Process Development O
3.2.P.2.4 Container Closure System O
3.2.P.2.5 Microbiological Attributes O
3.2.P.2.6 Compatibility O
3.2.P.3 Manufacture
3.2.P.3.1 Manufacturer(s) R
3.2.P.3.2 Batch Formula O
3.2.P.3.3 Description of Manufacturing Process and Process Controls O
3.2.P.3.4 Controls of Critical Steps and Intermediates O
3.2.P.3.5 Process Validation and/or Evaluation O
3.2.P.4 Control of Excipients
3.2.P.4.1 Specifications R
3.2.P.4.2 Analytical Procedures O
3.2.P.4.3 Validation of Analytical Procedures O
3.2.P.4.4 Justification of Specifications O
3.2.P.4.5 Excipients of Human or Animal Origin O
3.2.P.4.6 Novel Excipients O
3.2.P.5 Control of Drug Product
3.2.P.5.1 Specifications R
3.2.P.5.2 Analytical Procedures R
3.2.P.5.3 Validation of Analytical Procedures O
3.2.P.5.4 Batch Analyses R
3.2.P.5.5 Characterization of Impurities O
3.2.P.5.6 Justification of Specifications O
3.2.P.6 Reference Standards or Materials R
3.2.P.7 Container/Closure System R
4
3.2.P.8 Stability
3.2.P.8.1 Stability Summary and Conclusions IA
3.2.P.8.2 Post-Approval Stability Protocol and Stability Commitments O
3.2.P.8.3 Stability Data IA
3.3 Literature References IA

4
Is required for products that claim a shelf life of more than two years

40

DS-G-031-V2.2/130416